Brain lipoprotein lipase is responsive to nutritional and hormonal modulation.
Functional lipoprotein lipase activity was recently described in rat brain. The present study was performed to further characterize the biologic significance of brain lipoprotein lipase (heparin releasable component) and elucidate regulatory factors. Comparative studies were performed on tissue (brain, adipose, and heart) heparin releasable lipoprotein lipase in the fasted and diabetic (streptozotocin 100 mg/kg BW IP) rat. Both fasting (96 hours) and diabetes (ten days) significantly decreased brain (cortical) (P less than .05) and adipose (epididymal fat pad) (P less than .001) lipoprotein lipase activity. In contrast, heart muscle enzyme activity was significantly increased (P less than .001) in response to fasting and diabetes. Refeeding (Purina chow 96 hours) and insulin replacement (96 hours) reversed these changes in tissue lipoprotein lipase consequent to fasting and diabetes, respectively. There was a positive correlation between the changes in serum insulin concentration and adipose lipoprotein lipase, but there was no correlation between this parameter and brain or heart lipoprotein lipase. In addition, although T3 therapy normalized the low T3 state associated with both fasting and diabetes, it had no effect on the enzyme activity in the studied tissues. However, subsequent studies demonstrated that hypothyroidism (2 weeks post thyroidectomy) significantly decreased brain lipoprotein lipase activity (P less than .001) and increased both the adipose (P less than .025) and heart (P less than .025) enzyme activity. T3 replacement (0.8 micrograms/100 BW/d for 1 week) reversed the effects of hypothyroidism. However, the relationship between brain enzyme activity and serum T3 was nonlinear as hyperthyroidism tended to reduce brain LPL activity.(ABSTRACT TRUNCATED AT 250 WORDS)
Gavin
L A
LA
Division of Endocrinology-Metabolism, Veterans Administration Medical Center, San Francisco, CA 94121.
Cavalieri
R R
RR
Moeller
M
M
McMahon
F A
FA
Castle
J N
JN
Gulli
R
R
D000273:Adipose Tissue / Q000201:enzymology; D000818:Animals; D001921:Brain / Q000201:enzymology*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000201:enzymology*; D005215:Fasting; D005502:Food; D007037:Hypothyroidism / Q000188:drug therapy / Q000201:enzymology*; D007328:Insulin / Q000502:physiology / Q000627:therapeutic use; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008297:Male; D009206:Myocardium / Q000201:enzymology; D051381:Rats; D011919:Rats, Inbred Strains; D014284:Triiodothyronine / Q000502:physiology / Q000627:therapeutic use
D007328:Insulin; D014284:Triiodothyronine; D008071:Lipoprotein Lipase